Medulloblastoma (MB) is a highly aggressive embryonic tumour of the cerebellum and the most common malignant brain tumour of childhood. Despite a cure rate of approximately 70-75% among children aged 3 years, MB survivors continue to pay a high price, in terms of long-term adverse sequelae, for cure. A well defined neoplastic feature of MB is the genetic modifications of several different components of the Cyclin-dependent kinase (CDK)/Cyclin regulatory complex that plays a vital role in the cell cycle progression and transcriptional control. These genetic aberrations contribute to MB formation, suggesting that pharmacologic intervention to inhibit the CDKs activity may be a useful chemoprevention or therapeutic strategy for MB patients.
Grant Award – Studentship 2019-2020
Funding Award – £2000
Funding Awarded to – Dr Gianpiero di Leva
Research Location – University of Salford
Lead Researcher – Dr Gianpiero di Leva
0161 295 3864 